{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:13:00Z","timestamp":1793261580153,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,9,27]],"date-time":"2014-09-27T00:00:00Z","timestamp":1411776000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2014,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In the majority of cases, trigeminal neuralgia (TN) is a unilateral condition with ultra-short stabbing pain located along one or more branches of the trigeminal nerve. Although prophylactic pharmacological treatment is first choise, considering of insufficient effect or unacceptable side effects, neurosurgical treatment or lesion treatment should be considered. In addition to all these procedures mentioned above, one approach has been based on local intradermal and\/or submucosal injections of Botulinum Toxin Type A (BTX-A).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a randomized, double-blind, placebo-controlled since November 2012, and adopted local multi-point injection in 84 cases of classical TN with different doses of BTX-A. Eighty four patients were randomized into following groups: placebo (n\u2009=\u200928); BTX-A 25U (n\u2009=\u200927); BTX-A 75U (n\u2009=\u200929). Follow-up visits were conducted every week after the injection, and the overall duration of the study for each patient were 8\u00a0weeks to observe the pain severity, efficacy and adverse reactions at endpoint.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The visual analogue scale (VAS) scores of 25U and 75U groups reduced significantly compared to placebo as early as week 1, and sustained until week 8 throughout the study. There was no significant difference in VAS between 25U and 75U groups throughout the study. The response rates of 25U group (70.4%) and 75U group (86.2%) were significantly higher than placebo group (32.1%) at week 8, and there was no significant difference between 25U and 75U groups. Evaluation of the Patient Global Impression of Change (PGIC) demonstrated that 66.7% (25U group) and 75.9% (75U group) of the patients reported that their pain symptoms were \u2018much improved\u2019 or \u2018very much improved\u2019 versus 32.1% of the placebo group, and there was also no significant difference between 25U and 75U groups. All adverse reactions were graded as mild or moderate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>BTX-A injection in TN is safe and efficient. It is a useful treatment for refractory TN. Lower dose (25U) and high dose (75U) were similar in efficacy in short-term.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/1129-2377-15-65","type":"journal-article","created":{"date-parts":[[2014,9,27]],"date-time":"2014-09-27T11:01:08Z","timestamp":1411815668000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":146,"title":["Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: observation of therapeutic effect from a randomized, double-blind, placebo-controlled trial"],"prefix":"10.1186","volume":"15","author":[{"given":"Haifeng","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajun","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunqing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caihong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanchang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanjie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,9,27]]},"reference":[{"issue":"suppl 1","key":"1009_CR1","first-page":"9","volume":"24","author":"Headache Classification Subcommittee of the International Headache Society","year":"2004","unstructured":"Headache Classification Subcommittee of the International Headache Society: The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004, 24(suppl 1):9\u2013160.","journal-title":"Cephalalgia"},{"key":"1009_CR2","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1590\/S0004-282X2011000200016","volume":"69","author":"WK Campos","year":"2011","unstructured":"Campos WK, Linhares MN: A prospective study of 39 patients with trigeminal neuralgia treated with percutaneous balloon compression. Arq Neuropsiquiatr 2011, 69: 221\u2013226. 10.1590\/S0004-282X2011000200016","journal-title":"Arq Neuropsiquiatr"},{"key":"1009_CR3","first-page":"279","volume":"21","author":"JC Turp","year":"2000","unstructured":"Turp JC, Gobetti JP: Trigeminal neuralgia--an update. Compend Contin Educ Dent 2000, 21: 279\u2013282. 284, 287\u20138 passim;quiz 292","journal-title":"Compend Contin Educ Dent"},{"key":"1009_CR4","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1136\/pgmj.2009.080473","volume":"87","author":"JM Zakrzewska","year":"2011","unstructured":"Zakrzewska JM, McMillan R: Trigeminal neuralgia: the diagnosis and management of this excruciating and poorly understood facial pain. Postgrad Med J 2011, 87: 410\u2013416. 10.1136\/pgmj.2009.080473","journal-title":"Postgrad Med J"},{"issue":"Suppl 1","key":"1009_CR5","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1007\/s10194-011-0402-9","volume":"13","author":"L Bendtsen","year":"2012","unstructured":"Bendtsen L, Birk S, Kasch H, Aegidius K, Sorensen PS, Thomsen LL, Poulsen L, Rasmussen MJ, Kruuse C, Jensen R, Danish Headache Society: Reference programme: diagnosis and treatment of headache disorders and facial pain. Danish Headache Society, 2nd Edition. J Headache Pain 2012, 13(Suppl 1):S1-S29.","journal-title":"J Headache Pain"},{"key":"1009_CR6","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1177\/0333102412441721","volume":"32","author":"CJ Wu","year":"2012","unstructured":"Wu CJ, Lian YJ, Zheng YK: Botulinum toxin type A for the treatment of trigeminal neuralgia: results from a randomized, double-blind, placebo-controlled trial. Cephalalgia 2012, 32: 443\u2013450. 10.1177\/0333102412441721","journal-title":"Cephalalgia"},{"key":"1009_CR7","first-page":"625","volume":"21","author":"CJ Wu","year":"2011","unstructured":"Wu CJ, Shen JH, Chen Y, Lian YJ: Comparison of two different formulations of botulinum toxin A for the treatment of blepharospasm and hemifacial spasm. Turk Neurosurg 2011, 21: 625\u2013629.","journal-title":"Turk Neurosurg"},{"key":"1009_CR8","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1177\/0333102410364676","volume":"30","author":"SK Aurora","year":"2010","unstructured":"Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB: OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010, 30: 793\u2013803. 10.1177\/0333102410364676","journal-title":"Cephalalgia"},{"key":"1009_CR9","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1177\/0333102410364677","volume":"30","author":"HC Diener","year":"2010","unstructured":"Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB: OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010, 30: 804\u2013814. 10.1177\/0333102410364677","journal-title":"Cephalalgia"},{"key":"1009_CR10","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1177\/0333102410373154","volume":"30","author":"J Schoenen","year":"2010","unstructured":"Schoenen J: Botulinum toxin in headache treatment: finally a promising path. Cephalalgia 2010, 30: 771\u2013773. 10.1177\/0333102410373154","journal-title":"Cephalalgia"},{"key":"1009_CR11","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1177\/0333102410388529","volume":"31","author":"J Torgovnick","year":"2011","unstructured":"Torgovnick J: OnabotulinumtoxinA for the treatment of chronic migraine not quite there. Cephalalgia 2011, 31: 377. author reply 378\u20139 10.1177\/0333102410388529","journal-title":"Cephalalgia"},{"key":"1009_CR12","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1097\/00002508-200503000-00010","volume":"21","author":"N Allam","year":"2005","unstructured":"Allam N, Brasil-Neto JP, Brown G, Tomaz C: Injections of botulinum toxin type a produce pain alleviation in intractable trigeminal neuralgia. Clin J Pain 2005, 21: 182\u2013184. 10.1097\/00002508-200503000-00010","journal-title":"Clin J Pain"},{"key":"1009_CR13","first-page":"483","volume":"26","author":"JH Shen","year":"2011","unstructured":"Shen JH, Lian YJ, Zheng YK: Effect of botulinum toxin type a on clssic trigeminal neuralgia. Chin J Rehab Med 2011, 26: 483\u2013484.","journal-title":"Chin J Rehab Med"},{"key":"1009_CR14","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1097\/00002826-200209000-00006","volume":"25","author":"F Micheli","year":"2002","unstructured":"Micheli F, Scorticati MC, Raina G: Beneficial effects of botulinum toxin type a for patients with painful tic convulsif. Clin Neuropharmacol 2002, 25: 260\u2013262. 10.1097\/00002826-200209000-00006","journal-title":"Clin Neuropharmacol"},{"key":"1009_CR15","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1016\/j.tripleo.2009.03.021","volume":"109","author":"WC Ngeow","year":"2010","unstructured":"Ngeow WC, Nair R: Injection of botulinum toxin type A (BOTOX) into trigger zone of trigeminal neuralgia as a means to control pain. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010, 109: e47-e50.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"1009_CR16","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1590\/S0004-282X2011000100012","volume":"69","author":"EJ Piovesan","year":"2011","unstructured":"Piovesan EJ, Leite LS, Teive HG, Kowacs PA, Mulinari RA, Radunz V: Botulinum toxin type-A effect as a preemptive treatment in a model of acute trigeminal pain: a pre-clinical double-blind and placebo-controlled study. Arq Neuropsiquiatr 2011, 69: 56\u201363. 10.1590\/S0004-282X2011000100012","journal-title":"Arq Neuropsiquiatr"},{"key":"1009_CR17","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1212\/01.wnl.0000180940.98815.74","volume":"65","author":"EJ Piovesan","year":"2005","unstructured":"Piovesan EJ, Teive HG, Kowacs PA, Della CMV, Werneck LC, Silberstein SD: An open study of botulinum-A toxin treatment of trigeminal neuralgia. Neurology 2005, 65: 1306\u20131308. 10.1212\/01.wnl.0000180940.98815.74","journal-title":"Neurology"},{"key":"1009_CR18","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/01.wnf.0000172497.24770.b0","volume":"28","author":"U Turk","year":"2005","unstructured":"Turk U, Ilhan S, Alp R, Sur H: Botulinum toxin and intractable trigeminal neuralgia. Clin Neuropharmacol 2005, 28: 161\u2013162. 10.1097\/01.wnf.0000172497.24770.b0","journal-title":"Clin Neuropharmacol"},{"key":"1009_CR19","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1590\/S0004-282X2008000400012","volume":"66","author":"C Zuniga","year":"2008","unstructured":"Zuniga C, Diaz S, Piedimonte F, Micheli F: Beneficial effects of botulinum toxin type A in trigeminal neuralgia. Arq Neuropsiquiatr 2008, 66: 500\u2013503. 10.1590\/S0004-282X2008000400012","journal-title":"Arq Neuropsiquiatr"},{"key":"1009_CR20","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1136\/jnnp.2003.031286","volume":"75","author":"J Olesen","year":"2004","unstructured":"Olesen J, Steiner TJ: The International classification of headache disorders, 2nd edn (ICDH-II). J Neurol Neurosurg Psychiatry 2004, 75: 808\u2013811. 10.1136\/jnnp.2003.031286","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1009_CR21","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1054\/jpai.2002.27142","volume":"3","author":"GE Borodic","year":"2002","unstructured":"Borodic GE, Acquadro MA: The use of botulinum toxin for the treatment of chronic facial pain. J Pain 2002, 3: 21\u201327. 10.1054\/jpai.2002.27142","journal-title":"J Pain"},{"key":"1009_CR22","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.tripleo.2010.04.043","volume":"111","author":"B Bohluli","year":"2011","unstructured":"Bohluli B, Motamedi MH, Bagheri SC, Bayat M, Lassemi E, Navi F: Use of botulinum toxin A for drug-refractory trigeminal neuralgia: preliminary report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011, 111: 47\u201350. 10.1016\/j.tripleo.2010.04.043","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"1009_CR23","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.neuro.2005.01.017","volume":"26","author":"KR Aoki","year":"2005","unstructured":"Aoki KR: Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 2005, 26: 785\u2013793. 10.1016\/j.neuro.2005.01.017","journal-title":"Neurotoxicology"},{"key":"1009_CR24","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/S0021-5155(99)00197-5","volume":"44","author":"H Ishikawa","year":"2000","unstructured":"Ishikawa H, Mitsui Y, Yoshitomi T, Mashimo K, Aoki S, Mukuno K: Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Jpn J Ophthalmol 2000, 44: 106\u2013109. 10.1016\/S0021-5155(99)00197-5","journal-title":"Jpn J Ophthalmol"},{"key":"1009_CR25","doi-asserted-by":"publisher","first-page":"4981","DOI":"10.1523\/JNEUROSCI.5490-08.2009","volume":"29","author":"J Meng","year":"2009","unstructured":"Meng J, Ovsepian SV, Wang J, Pickering M, Sasse A, Aoki KR: Activation of TRPV1 mediates calcitonin gene-related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum boxin with anti-nociceptive potential. J Neurosic 2009, 29: 4981\u20134992. 10.1523\/JNEUROSCI.5490-08.2009","journal-title":"J Neurosic"},{"key":"1009_CR26","doi-asserted-by":"publisher","first-page":"7723","DOI":"10.1073\/pnas.96.14.7723","volume":"96","author":"CJ Woolf","year":"1999","unstructured":"Woolf CJ, Costigan M: Transcriptional and posttranslational plasticity and the generation of inflammatory pain. Proc Natl Acad Sci 1999, 96: 7723\u20137730. 10.1073\/pnas.96.14.7723","journal-title":"Proc Natl Acad Sci"},{"key":"1009_CR27","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s11916-999-0069-y","volume":"3","author":"BM Guyer","year":"1999","unstructured":"Guyer BM: Mechanism of botulinum toxin in the relief of chronic pain. Curr Rev Pain 1999, 3: 427\u2013431. 10.1007\/s11916-999-0069-y","journal-title":"Curr Rev Pain"},{"key":"1009_CR28","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1053\/mda.2002.24423","volume":"48","author":"WJ Binder","year":"2002","unstructured":"Binder WJ, Brin MF, Blitzer A: Botulinum toxin type A (BOTOX) for treatment of migraine. Dis Mon 2002, 48: 323\u2013335. 10.1053\/mda.2002.24423","journal-title":"Dis Mon"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1129-2377-15-65\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1129-2377-15-65.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1129-2377-15-65.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T02:00:49Z","timestamp":1630548049000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/1129-2377-15-65"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,27]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["1009"],"URL":"https:\/\/doi.org\/10.1186\/1129-2377-15-65","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725299667.793502852","asserted-by":"object"}]},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,27]]},"assertion":[{"value":"17 August 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"65"}}